Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)

BACKGROUND


Biliary Tract Cancer (BTC)

- Aggressive cancer with a poor prognosis
- Heterogenous disease consisting of distinct subgroups
- Intra and extra-hepatic cholangiocarcinoma, gallbladder, or ampullary
- No approved agents exist for the first-line treatment of advanced BTC
- Current standard of care: gemcitabine + cisplatin
- Median overall survival (OS) 11.7 months (ABC-02)¹
- Resistance to chemotherapy is associated with poor survival
- Effective new agents and combinations are required


NUC-1031: A ProTide transformation of gemcitabine

- A new class of anti-cancer agents
- Overcomes key gemcitabine resistance mechanisms²
- Cellular uptake independent of nucleoside transporters (hENT1)
- Activation independent of deoxycytidine kinase (dCK)
- Protected from breakdown by cytidine deaminase (CDA)
- In comparison to gemcitabine, NUC-1031 has³
- Greater plasma stability (t_{1/2} 8.3 hours vs 1.5 hours)
- Increased intracellular levels of active anti-cancer metabolite, dFdCTP (217x)
- Reduced toxic metabolites

NUC-1031 bypasses the key cancer resistance pathways of gemcitabine



NUC-1031



Phase 1b ABC-08 study: NUC-1031 + cisplatin⁴

- Favorable safety profile that was tolerated over multiple cycles
- Encouraging efficacy with activity across all BTC subtypes (44% ORR*)

ERENCES: 1. Valle et al. N Engl J Med 2010; 362:1273-1281. 2. Slusarczyk et al. J Med Chem 2014; 57:1531-1542. 3. Blagden et al. Br J Cancer 2018; 119:815-822. 4. McNamara MG et al. O BREVIATIONS: BTC: biliary tract cancer OS: overall survival hENT1: human equilibrative nucleoside transporter 1 dCK: deoxycytidine kinase CDA: cytidine deaminase dFdCTP: d

Efficacy evaluable patients

NUTIDE 121 **INCLUSION CRITERIA** Previously untreated histologically or cytologically-confirmed adenocarcinoma of the biliary tract (intra and extra-hepatic cholangiocarcinoma, gallbladder, or ampullary cancers) that is locally advanced, unresectable or metastatic

- ≥18 years of age
- Life expectancy \geq 16 weeks
- ECOG PS 0 or 1

NUC-1031

725 mg/m²

cisplatin

25 mg/m²

dosing on days 1 & 8

of a 21-day cycle*

*until unacceptable toxicity or progressive disease

cologist 2021; 26(4)669-678.

Adequate biliary drainage with no evidence of ongoing infection


RANDOMIZATION STRATA

Measurable Disease
Metastatic Disease


Jennifer J Knox¹, Mairéad G McNamara², Lipika Goyal³, David P Cosgrove⁴, Christoph Springfeld⁵, Katrin M Sjoquist⁶, Joon Oh Park⁷, Helena Verdaguer⁸, Chiara Braconi⁹, Paul J. Ross¹⁰, Do-Youn Oh¹¹, Michael Raphael¹², Aimery de Gramont¹³, Rachna T Shroff¹⁴, John R Zalcberg¹⁵, Daniel H. Palmer¹⁶, Juan W Valle²

1) Princess Margaret Cancer Centre, Toronto, Canada 2) University of Manchester / The Christie, Manchester, UK 3) Massachusetts General Hospital, ision of Medical Oncology, Vancouver Cancer Center, Compass Oncology, Vancouver, US 5) University Hospital Heidelberg, Germany public of Korea 8) Vall d'Hebron University Hospital and Institute of Oncology (VHIO), CIBERONC, TTD Group, Barcelona, Spain 9) University c West of Scotland Cancer Centre, Glasgow, UK 10) Guy's Hospital, London, UK 11) Seoul National University Hospital, Cancer te. Seoul National University College of Medicine. Seoul. Republic of Korea 12) Sunnybrook Health Science Center, Toronto, Canada 13) Franco-British Institute, Levallois-Perret, France 14) Division of Hematology/Oncology, Department of Medicine, University of Arizona Cancer Center Tucson, US 15) Monash University, Melbourne, Australia 16) University of Liverpool, Liverpool, U

Presentation Numbe **59TiP** NCT Number: NCT04163900 EudraCT Numbe 2019-001025-028 Email jennifer.knox@uhn.c




NuTide:121 (Statistical Plan)



[#] DIP = Difference in observed proportions (vs. an estimated 19.0%) for statistical significance. Measu DIM = Difference in observed medians (vs. an estimated 11.7 months) for statistical significance.






SUMMARY



- Global Phase III study at ~126 sites across North America, Europe and Asia-Pacific
- NUC-1031 + cisplatin has the potential to improve survival outcomes in patients with BTC
- Further study information: NuTide121@nucana.com

Anatomic Site of Disease
Geography



PRIMARY ENDPOINTS


• Overall Survival • Objective Response Rate

SECONDARY ENDPOINTS

hate AE: adverse event DLT: dose-limiting toxicity ITT: intention to treat ECOG: eastern cooperative oncology group ORR: objective response rate PS: performance statu: al DoR: duration of response DIM: difference in observed means DIP: difference in observed proportions

• PFS • DoR • Safety • PK • QoL





The first author has no conflicts of interest to d